3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 3
8
Phase 1/2
8
Phase 1
8
Phase NA
7
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
75
Lung Neoplasms
48
Small Cell Lung Carcinoma
11
Neoplasms
10
NSCLC
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Mesothelioma
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Head and Neck Neoplasms
4
Adenocarcinoma of Lung
4
Liver Neoplasms
3
Hematologic Neoplasms
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Sarcoma
2
Recurrence
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Laryngeal Neoplasms
2
Interventions
Gefitinib
1
Erlotinib Hydrochloride
1
AZD3759
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Respiratory Tract Diseases
×
Thoracic
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled